Trial Profile
A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Crisantaspase; Crisantaspase; Cyclophosphamide; Daunorubicin; Dexamethasone; Ifosfamide; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 09 Feb 2023 This trial has been completed in Poland, according to European Clinical Trials (5 Dec 2022)Database record.
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 13 Oct 2022 Planned End Date changed from 14 Nov 2022 to 22 Nov 2022.